Montegen (Montelukast)

Montelukast selectively blocks the cysteinyl leukotriene receptor CysLT1. By preventing leukotrienes from binding, it reduces bronchoconstriction, mucus production, and inflammatory cell recruitment, leading to improved airway patency and less allergic inflammation.

The appropriate dose of Montegen is set by a qualified prescriber based on the patient’s age, weight, severity of disease, and response to therapy. No fixed regimen is provided here; clinicians tailor the regimen to individual needs.

Montelukast is classified as pregnancy category B, indicating no evidence of risk in animal studies and limited human data. It is generally considered safe when clearly needed, but clinicians should weigh benefits against potential risks. Breastfeeding mothers should monitor the infant for any adverse effects.

To request Montegen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montegen (montelukast) belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting bronchodilators. It is particularly useful for patients who need add‑on therapy, have difficulty using inhalers, or have co‑existing allergic rhinitis. Efficacy differs by individual response, so clinicians often combine it with other agents.

Montegen should be stored at room temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture, direct sunlight and excessive heat to maintain stability.

Montegen is taken orally, usually as a whole tablet with or without food. The exact timing (e.g., morning or evening) is determined by the prescribing clinician based on the patient’s treatment plan.

Serious risks, though rare, include severe allergic reactions such as rash or angioedema, mood alterations including depression or suicidal thoughts, elevated liver enzymes, and rare dermatologic events like Stevens‑Johnson syndrome. Patients should seek immediate medical attention if any of these occur.

Montegen should be avoided in individuals with a known hypersensitivity to montelukast or any component of the formulation. Caution is also advised for patients with severe liver impairment, and it is not recommended for use in children under the age approved for the specific dosage form.